GoodRx Holdings, Inc. reported its financial results for the third quarter of 2024, with total revenue increasing 8% year-over-year to $195.3 million. Adjusted Revenue also rose 3% to $195.3 million, reflecting continued business momentum.
Prescription transactions revenue grew 4% to $140.4 million, driven by a 7% increase in Monthly Active Consumers, primarily from organic growth and integrated savings program expansion. However, subscription revenue decreased 8% to $21.3 million due to the sunset of the Kroger Savings Club program.
Pharma Manufacturer Solutions revenue showed robust growth, increasing 77% to $28.1 million, partly due to a $10.0 million client contract termination payment recognized as a reduction of revenue in the prior year quarter and organic expansion. Net income significantly improved to $4.0 million compared to a net loss of $38.5 million in the prior year period.
Adjusted EBITDA increased 21% year-over-year to $65.0 million, resulting in an Adjusted EBITDA Margin of 33.3%, up from 28.1%. This margin expansion was attributed to top-line growth and run-rate savings from prior restructuring efforts.
For the fourth quarter of 2024, GoodRx anticipates revenue of approximately $200 million and an Adjusted EBITDA Margin of about 34%. The full year 2024 guidance projects revenue of approximately $794 million and Adjusted EBITDA between $255 million and $260 million, representing 17% to 20% growth over 2023.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.